146 related articles for article (PubMed ID: 15675579)
21. [Current status and future perspectives in chemotherapy for testicular cancer].
Kawai K
Gan To Kagaku Ryoho; 2003 Feb; 30(2):171-80. PubMed ID: 12610862
[TBL] [Abstract][Full Text] [Related]
22. The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors.
Bokemeyer C; Hartmann JT; Kuczyk MA; Truss MC; Beyer J; Jonas U; Kanz L
World J Urol; 1996; 14(6):354-9. PubMed ID: 8986035
[TBL] [Abstract][Full Text] [Related]
23. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience.
Farhat F; Culine S; Théodore C; Békradda M; Terrier-Lacombe MJ; Droz JP
Cancer; 1996 Mar; 77(6):1193-7. PubMed ID: 8635143
[TBL] [Abstract][Full Text] [Related]
24. The present and future of combination chemotherapy in bladder cancer.
Culine S
Semin Oncol; 2002 Jun; 29(3 Suppl 9):32-9. PubMed ID: 12094336
[TBL] [Abstract][Full Text] [Related]
25. Different Chemotherapy Regimens in the Management of Advanced or Metastatic Urothelial Cancer: a Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Wang Y; Xu L; Meng X; Qin Z; Wang Y; Chen C; Wang Y; Zhou X; Zhang Q; Xia J; Song N
Cell Physiol Biochem; 2018; 50(1):1-14. PubMed ID: 30293075
[TBL] [Abstract][Full Text] [Related]
26. Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen.
Takahashi T; Higashi S; Nishiyama H; Segawa T; Nakamura E; Kinoshita H; Itoh N; Yamamoto S; Kamoto T; Habuchi T; Ogawa O
Jpn J Clin Oncol; 2006 Feb; 36(2):104-8. PubMed ID: 16418182
[TBL] [Abstract][Full Text] [Related]
27. Third-line gemcitabine monotherapy for platinum-resistant advanced urothelial cancer.
Soga N; Kise H; Arima K; Sugimura Y
Int J Clin Oncol; 2010 Aug; 15(4):376-81. PubMed ID: 20333430
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
29. Future directions in the chemotherapy of ovarian cancer.
Ozols RF
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-86-S15-90. PubMed ID: 9346230
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
[TBL] [Abstract][Full Text] [Related]
31. [Combination therapy consisting of gemcitabine, docetaxel and carboplatin as a second-line chemotherapy for patients with MVAC-treated metastatic urothelial carcinoma].
Inoue T; Obara T; Saito M; Kumazawa T; Narita S; Horikawa Y; Yuasa T; Tsuchiya N; Satoh S; Habuchi T
Hinyokika Kiyo; 2008 Sep; 54(9):581-5. PubMed ID: 18975570
[TBL] [Abstract][Full Text] [Related]
32. Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis.
Miyata Y; Nomata K; Ohba K; Matsuo T; Sagara Y; Kanetake H; Sakai H
Cancer Chemother Pharmacol; 2012 Sep; 70(3):451-9. PubMed ID: 22864875
[TBL] [Abstract][Full Text] [Related]
33. Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group.
Pectasides D; Aravantinos G; Kalofonos H; Kiamouris C; Bafaloukos D; Xiros N; Nicolaides C; Visvikis A; Dimopoulos MA
Ann Oncol; 2001 Oct; 12(10):1417-22. PubMed ID: 11762814
[TBL] [Abstract][Full Text] [Related]
34. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.
Yeshchina O; Badalato GM; Wosnitzer MS; Hruby G; RoyChoudhury A; Benson MC; Petrylak DP; McKiernan JM
Urology; 2012 Feb; 79(2):384-90. PubMed ID: 22196406
[TBL] [Abstract][Full Text] [Related]
35. [Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma].
Inoue T; Ohyama C; Horikawa Y; Togashi H; Matsuura S; Tsuchiya N; Satoh S; Sato K; Habuchi T; Saito S; Hoshi S; Arai Y; Kato T
Hinyokika Kiyo; 2004 Apr; 50(4):273-7. PubMed ID: 15188623
[TBL] [Abstract][Full Text] [Related]
36. [New combination chemotherapy in urological cancers].
Hattori K; Akaza H
Gan To Kagaku Ryoho; 2000 Mar; 27(3):382-7. PubMed ID: 10740631
[TBL] [Abstract][Full Text] [Related]
37. [Results of chemotherapy and salvage surgery for advanced testicular cancer].
Saiki S; Meguro N; Maeda O; Kinouchi T; Kuroda M; Usami M; Kotake T; Miki T
Hinyokika Kiyo; 1999 Nov; 45(11):777-81. PubMed ID: 10637743
[TBL] [Abstract][Full Text] [Related]
38. [Gemcitabine and pemetrexed in genito-urinary tumors treatment].
Fléchon A
Bull Cancer; 2007; 94 Spec No Actualites():S116-21. PubMed ID: 17845980
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma.
Urakami S; Fujii Y; Yamamoto S; Yuasa T; Kitsukawa S; Sakura M; Yano A; Saito K; Masuda H; Yonese J; Fukui I
Urol Oncol; 2014 Jan; 32(1):35.e1-7. PubMed ID: 23562233
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
Bellmunt J; Albanell J; Paz-Ares L; Climent MA; González-Larriba JL; Carles J; de la Cruz JJ; Guillem V; Díaz-Rubio E; Cortés-Funes H; Baselga J;
Cancer; 2002 Aug; 95(4):751-7. PubMed ID: 12209718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]